Phase 4
N=40
Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Inflammatory Bowel Disease
Bottom Line
View on ClinicalTrials.gov: NCT00746395 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcome: Primary: Complete Small Bowel Transit — 75; 95 percentage of subjects with passage
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Lubiprostone (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- All
- Sponsor
- University of South Alabama
- Primary completion
- Sep 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Small Bowel Transit |
75; 95 | — |
| SECONDARY Small Bowel Transit |
188.1; 218.9 | — |
Summary
This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers
Exclusion Criteria
- Gi disorders, gi surgery, cardiac, renal, or hepatic insufficiency, severe diarrhea
Data sourced from ClinicalTrials.gov (NCT00746395). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.